Search

Author/Creator Forward, Nick

1. 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab. (9th November 2020)

Authors:
Berinstein, Neil; Bence-Bruckler, Isabelle; Forward, Nick; Laneuville, Pierre; Mangel, Joy; Stewart, Douglas; Amitai, Irina; Klein, Gail; Pennell, Nancy; Rashedi, Iran; Roos, Kim; Bramhecha, Yogesh; Conlon, Rebekah
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A217
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab. (9th November 2020)

Authors:
Berinstein, Neil; Bence-Bruckler, Isabelle; Forward, Nick; Laneuville, Pierre; Mangel, Joy; Stewart, Douglas; Amitai, Irina; Klein, Gail; Pennell, Nancy; Rashedi, Iran; Roos, Kim; Bramhecha, Yogesh; Conlon, Rebekah
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A381
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search